Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XOMA 052 |
Trade Name | |
Synonyms | Gevokizumab|VPM087 |
Drug Descriptions |
XOMA 052 (gevokizumab) is a monoclonal antibody that targets interleukin-1 beta (IL1B) and reduces the binding affinity of IL1B to IL1R1 and IL-1RAcP receptors, potentially resulting in decreased inflammatory response and reduced ILB1 signaling (PMID: 20410301, PMID: 24194526, PMID: 21048425). |
DrugClasses | |
CAS Registry Number | 1129435-60-4 |
NCIT ID | C97945 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 | Bevacizumab Fluorouracil Irinotecan Leucovorin XOMA 052 | 0 | 1 |
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 | Bevacizumab Fluorouracil Leucovorin Oxaliplatin XOMA 052 | 0 | 1 |
Cabozantinib + XOMA 052 | Cabozantinib XOMA 052 | 0 | 1 |
Paclitaxel + Ramucirumab + XOMA 052 | Paclitaxel Ramucirumab XOMA 052 | 0 | 1 |
XOMA 052 | XOMA 052 | 0 | 1 |